2. Signaling Pathways
  3. Cell Cycle/DNA Damage
  4. HMG Family

HMG Family

High Mobility Group Family

The high mobility group (HMG) proteins are a superfamily of abundant and ubiquitous nuclear proteins that bind to DNA and nucleosomes and induce structural changes in the chromatin fiber. HMG family proteins include HMGB, HMGN, and HMGA subfamilies, which are highly evolutionarily conserved nuclear proteins. The three HMG families in modulating developmental processes and tumorigenesis. As the most abundant protein among all the HMG family members and the second-most abundant protein in the nucleus, HMGB1 (also known as HMG1, HMG-1, and amphoterin) is widely expressed in mammalian cells and tissues. HMGB1 is a type of alarm signal protein that promotes the recruitment and activation of inflammation-promoting immune cells. HMG proteins is developmentally regulated and that changes in HMG protein levels alter the cellular phenotype and can lead to de

HMG Family Related Products (3):

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-P9928
    Alirocumab
    Alirocumab is an anti-PCSK9 human monoclonal antibody. Alirocumab inhibits PCSK9. Alirocumab reduces NLRP3 inflammasome, regulates Nrf2/HO-1, HMGB1/NF-κB and Fractalkine/CX3CR1. Alirocumab increases the ability of the liver to bind LDL-cholesterol (LDL-C) and reduces levels of LDL-C in blood. Alirocumab improves atherosclerosis and inflammation.
    Alirocumab
  • HY-P9928A
    Alirocumab (anti-PCSK9)
    		98.24%
    Alirocumab (anti-PCSK9) is an anti-PCSK9 human monoclonal antibody. Alirocumab (anti-PCSK9) inhibits PCSK9. Alirocumab (anti-PCSK9) reduces NLRP3 inflammasome, regulates Nrf2/HO-1, HMGB1/NF-κB and Fractalkine/CX3CR1. Alirocumab (anti-PCSK9) increases the ability of the liver to bind LDL-cholesterol (LDL-C) and reduces levels of LDL-C in blood. Alirocumab (anti-PCSK9) improves atherosclerosis and inflammation.
    Alirocumab (anti-PCSK9)
  • HY-116940
    Sm4
    		Inhibitor 99.37%
    Sm4 is a SOX18 inhibitor. Sm4 shows SOX18-DNA binding inhibitory activity. Sm4 selectively affects SOX18 transcriptional output in vitro. Sm4 blocks SoxF transcriptional activity in vivo. Sm4 can be used for cancer metastasis and vascular cancers research.
    Sm4